References
References1. Ferrario CM. Role ofangiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst 2006;7:3–14.FerrarioCMRole ofangiotensin II in cardiovascular disease therapeutic implications of more than a century of research.J Renin Angiotensin Aldosterone Syst200673-142. Dielis AW, Smid M, Spronk HM, et al. The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems. Hypertension 2005;46:1236–1242.DielisAW]]SmidM]]SpronkHM&etal;The prothrombotic paradox of hypertension: role of the renin-angiotensin and kallikrein-kinin systems.Hypertension2005461236-12423. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–153.YusufS]]SleightP]]PogueJ&etal;Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.N Engl J Med2000342145-1534. ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547–1559.ONTARGET InvestigatorsYusufS]]TeoKK]]PogueJ&etal;Telmisartan, ramipril, or both in patients at high risk for vascular events.N Engl J Med20083581547-15595. Basile J, Toth P. Angiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy. South Med J 2009;102(S1 online):S1–S12.BasileJ]]TothPAngiotensin receptor blockers: role in hypertension management, cardiovascular risk reduction, and nephropathy.South Med J2009102S1 onlineS1-S126. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.LewisEJ]]HunsickerLG]]ClarkeWR&etal;Collaborative Study GroupRenoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.N Engl J Med2001345851-8607. Pfeffer MA, McMurray JJ, Velazquez EJ, et al; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003;349:1893–1906.PfefferMA]]McMurrayJJ]]VelazquezEJ&etal;Valsartan in Acute Myocardial Infarction Trial InvestigatorsValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.N Engl J Med20033491893-19068. Alderman MH, Ooi WL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997;10:1–8.AldermanMH]]OoiWL]]CohenH&etal;Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients.Am J Hypertens1997101-89. Rockman HA, Juneau C, Chatterjee K, et al. Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1989;64:1344–1348.RockmanHA]]JuneauC]]ChatterjeeK&etal;Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease.Am J Cardiol1989641344-134810. Parving HH, Persson F, Lewis JB, et al; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433–2446.ParvingHH]]PerssonF]]LewisJB&etal;AVOID Study InvestigatorsAliskiren combined with losartan in type 2 diabetes and nephropathy.N Engl J Med20083582433-2446
